Clinical Trial Update: Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating medroxyprogesterone, interferon, and/or aldesleukin for metastatic renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Aldesleukin (interleukin-2)
• Interferon (interferon)
• Medroxyprogesterone (medroxyprogesterone)

Snippet

Sponsor: Centre Leon Berard | Conditions: Kidney Cancer | Phase 3 | Status: COMPLETED